MA53909A - Compositions et méthodes de stimulation ovarienne contrôlée - Google Patents
Compositions et méthodes de stimulation ovarienne contrôléeInfo
- Publication number
- MA53909A MA53909A MA053909A MA53909A MA53909A MA 53909 A MA53909 A MA 53909A MA 053909 A MA053909 A MA 053909A MA 53909 A MA53909 A MA 53909A MA 53909 A MA53909 A MA 53909A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- ovarian stimulation
- controlled ovarian
- controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862746812P | 2018-10-17 | 2018-10-17 | |
EP18203167 | 2018-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53909A true MA53909A (fr) | 2022-01-26 |
Family
ID=68344788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053909A MA53909A (fr) | 2018-10-17 | 2019-10-17 | Compositions et méthodes de stimulation ovarienne contrôlée |
Country Status (17)
Country | Link |
---|---|
US (1) | US20210353717A1 (fr) |
EP (1) | EP3866833A1 (fr) |
JP (1) | JP2022505191A (fr) |
KR (1) | KR20210079276A (fr) |
CN (1) | CN112789053A (fr) |
AU (1) | AU2019363279A1 (fr) |
BR (1) | BR112021005019A2 (fr) |
CA (1) | CA3110205A1 (fr) |
CL (2) | CL2021000928A1 (fr) |
CO (1) | CO2021005872A2 (fr) |
IL (1) | IL280750A (fr) |
JO (1) | JOP20210025A1 (fr) |
MA (1) | MA53909A (fr) |
MX (1) | MX2021004383A (fr) |
PH (1) | PH12021550417A1 (fr) |
SG (1) | SG11202102340RA (fr) |
WO (1) | WO2020079127A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL272763B2 (en) | 2017-09-01 | 2024-02-01 | Ferring Bv | The composition for controlled stimulation of the ovary |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003022303A2 (fr) * | 2001-09-12 | 2003-03-20 | Applied Research Systems Ars Holding N.V. | Utilisation de hcg et de lh in dans l'hyperstimulation ovarienne controlee |
EP1364658A1 (fr) * | 2002-05-24 | 2003-11-26 | Applied Research Systems ARS Holding N.V. | Utilisation de rapports variables de gonadotrophines dans l'hyperstimulation ovarienne contrôlée |
TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
-
2019
- 2019-10-17 CA CA3110205A patent/CA3110205A1/fr active Pending
- 2019-10-17 MA MA053909A patent/MA53909A/fr unknown
- 2019-10-17 WO PCT/EP2019/078170 patent/WO2020079127A1/fr active Application Filing
- 2019-10-17 KR KR1020217008853A patent/KR20210079276A/ko unknown
- 2019-10-17 CN CN201980064065.3A patent/CN112789053A/zh active Pending
- 2019-10-17 JO JOP/2021/0025A patent/JOP20210025A1/ar unknown
- 2019-10-17 SG SG11202102340RA patent/SG11202102340RA/en unknown
- 2019-10-17 JP JP2021521140A patent/JP2022505191A/ja active Pending
- 2019-10-17 MX MX2021004383A patent/MX2021004383A/es unknown
- 2019-10-17 US US17/285,314 patent/US20210353717A1/en active Pending
- 2019-10-17 AU AU2019363279A patent/AU2019363279A1/en active Pending
- 2019-10-17 BR BR112021005019-1A patent/BR112021005019A2/pt unknown
- 2019-10-17 EP EP19794444.0A patent/EP3866833A1/fr active Pending
-
2021
- 2021-02-09 IL IL280750A patent/IL280750A/en unknown
- 2021-02-26 PH PH12021550417A patent/PH12021550417A1/en unknown
- 2021-04-15 CL CL2021000928A patent/CL2021000928A1/es unknown
- 2021-05-04 CO CONC2021/0005872A patent/CO2021005872A2/es unknown
-
2022
- 2022-03-29 CL CL2022000779A patent/CL2022000779A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2021000928A1 (es) | 2021-10-22 |
WO2020079127A1 (fr) | 2020-04-23 |
PH12021550417A1 (en) | 2021-09-20 |
IL280750A (en) | 2021-04-29 |
TW202027780A (zh) | 2020-08-01 |
CO2021005872A2 (es) | 2021-09-20 |
CL2022000779A1 (es) | 2022-11-25 |
CN112789053A (zh) | 2021-05-11 |
JP2022505191A (ja) | 2022-01-14 |
AU2019363279A1 (en) | 2021-03-11 |
CA3110205A1 (fr) | 2020-04-23 |
US20210353717A1 (en) | 2021-11-18 |
SG11202102340RA (en) | 2021-05-28 |
KR20210079276A (ko) | 2021-06-29 |
BR112021005019A2 (pt) | 2021-06-08 |
EP3866833A1 (fr) | 2021-08-25 |
MX2021004383A (es) | 2021-06-04 |
JOP20210025A1 (ar) | 2021-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
MA46102A (fr) | Composés de tétracycline et méthodes de traitement | |
ZA201908496B (en) | Small molecule modulators of human sting | |
MA50205A (fr) | Formulation de nicotine | |
MA47611A (fr) | Compositionset méthodes de transduction tumorale | |
ES2975278T3 (es) | Inhibición de crecimiento cristalino de roflumilast | |
MA45407A (fr) | Compositions et méthodes de déplétion de cellules | |
DK3377612T3 (da) | Funktionel ekspression af monooxygenaser og fremgangsmåder til anvendelse | |
MA43134A (fr) | Compositions et méthodes de transduction tumorale | |
DK3244965T3 (da) | Behandling af hovedpine med elektrisk stimulering | |
JP2018172409A5 (ja) | 15−hepeを含む組成物および同組成物を使用する方法 | |
MA41119A (fr) | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique | |
DK3428274T3 (da) | Anvendelse af nukleosominteragerende proteindomæner til forbedring af målrettet genommodifikation | |
GB201709959D0 (en) | Small molecule modulators of human STING | |
MA48730A (fr) | Compositions et méthodes de traitement de synucléinopathies | |
SG11202102636UA (en) | Modulators of pnpla3 expression | |
DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
MA51337A (fr) | Inhibiteurs spiro exo-aza de l'interaction ménine-mll | |
MA54143A (fr) | Compositions et méthodes | |
IL283967A (en) | Modulators of hsd17b13 expression | |
GB2574740B (en) | Characterisation of emulsion stability | |
GB201700711D0 (en) | Application of an optical effect | |
MA44862A (fr) | Formulations de fulvestrant et méthodes d'utilisation de celles-ci | |
EP3574047A4 (fr) | Compositions d'émulsion et leurs procédés d'utilisation | |
DK3532072T3 (da) | Behandling af glaukom |